Trial Number

377-23

Conditions

Headache, Migraine & Headache

Participant Age Range

12 years to 17 years

Participant Gender

Any

Enrolling Participants

Yes

Overview

“A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine: PIONEER-PEDS2”

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

Provider

Jasmin M Dao, MD

Neurology - Pediatric, Pediatrics
+ More
Long Beach, Fountain Valley
View Profile

Location

Miller Children’s & Women’s Hospital Long Beach

2801 Atlantic Avenue
Long Beach
(562) 933-5437
Location Details

Related Clinical Trials

Click on the category you are interested in.

Neurological Care Pediatric Care Pediatric Specialty Care Miller Children's & Women's Hospital Long Beach
Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.